Mitchell Lab News Today

Human history was forever changed with the discovery of antibiotics in 1928. Infectious diseases such as pneumonia, tuberculosis and sepsis were widespread and lethal until penicillin made them treatable. Surgical procedures that once came with a high risk of infection became safer and&#x2...

Recent research reveals a breakthrough in lung repair, showing how delivering VEGFA via lipid nanoparticles can significantly repair damaged blood vessels, akin to plumbing repairs. This method, validated in animal models, offers promising insights into treating respiratory virus damages, enhancing

Researchers from the University of Pennsylvania, led by Michael Mitchell, are now breaking through the blood-brain barrier, a long-standing biological barrier.

In recent years, cancer researchers have hailed the arrival of chimeric antigen receptor T cell (CAR T) therapy, which has delivered promising results, transforming the fight against various forms of cancer. The process involves modifying patients' T-cells to target cancer cells, resulting in remarkable success rates for previously intractable forms of cancer.

Chimeric Antigen Receptor T-cell (CAR T) therapy has delivered promising results, transforming the fight against various forms of cancer, but for many, the therapy comes with severe and potentially lethal side effects. Now a research team led by Michael Mitchell of the University of Pennsylvania has found a solution that could help CAR T therapies reach their full potential while minimizing severe side effects.

Pre-eclampsia is a leading cause of stillbirths and prematurity worldwide, occurring in 3 – 8 % of pregnancies. A disorder characterized by high maternal blood pressure, it results from insufficient vasodilation in the placenta, restricting blood flow from the mother to the fetus.

Wednesday, March 2 at 10am ET / 3pm GMT / 4pm CET...